Hirofumi Kawakubo

Keio University — Japan

Medicine · Health Sciences

35h-index6.1kcitations355works1.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Esophageal Cancer Research and Treatment(181), Gastric Cancer Management and Outcomes(158), Esophageal and GI Pathology(109), Metastasis and carcinoma case studies(52), Lung Cancer Diagnosis and Treatment(46)

Publications354 total

Supplemental Table S1 from Targeting KRAS Inhibitor–Resistant Pancreatic Cancer with an MUC1-C Antibody–Drug Conjugate
2025Open Access
Figure S8 from Targeting KRAS Inhibitor–Resistant Pancreatic Cancer with an MUC1-C Antibody–Drug Conjugate
2025Open Access
Figure S6 from Targeting KRAS Inhibitor–Resistant Pancreatic Cancer with an MUC1-C Antibody–Drug Conjugate
2025Open Access
Figure S2 from Targeting KRAS Inhibitor–Resistant Pancreatic Cancer with an MUC1-C Antibody–Drug Conjugate
2025Open Access
Figure S5 from Targeting KRAS Inhibitor–Resistant Pancreatic Cancer with an MUC1-C Antibody–Drug Conjugate
2025Open Access
Figure S4 from Targeting KRAS Inhibitor–Resistant Pancreatic Cancer with an MUC1-C Antibody–Drug Conjugate
2025Open Access
Figure S7 from Targeting KRAS Inhibitor–Resistant Pancreatic Cancer with an MUC1-C Antibody–Drug Conjugate
2025Open Access
Safety and efficacy of conversion therapy for metastatic esophageal cancer: exploratory analysis of JCOG1314
Esophagus·2025
Targeting KRAS Inhibitor–Resistant Pancreatic Cancer with an MUC1-C Antibody–Drug Conjugate
Clinical Cancer Research·2025· 2 citedOpen Access
Current status and clinical usefulness of genomic panel testing using PleSSision-160 in resectable esophageal squamous cell carcinoma
European Journal of Surgical Oncology·2025Open Access
Successful repeated endoscopic balloon dilatation for esophageal stricture as chronic graft‐versus‐host disease
Annals of Hematology·2025Open Access
135. COMPARISON BETWEEN NEOADJUVANT-CHEMORADIOTHERAPY FOLLOWED BY SURGERY AND DEFINITIVE CHEMORADIOTHERAPY FOR SURVIVAL IN PATIENTS WITH RESECTABLE ESOPHAGEAL SQUAMOUS CELL CARCINOMA (JCOG2305A)
Diseases of the Esophagus·2025
199. THE CORRELATION BETWEEN HISTOPATHOLOGICAL RESPONSE OF NIVOLUMAB-CONTAINING NEOADJUVANT CHEMOTHERAPY AND IMMUNE CELL TYPES FOR LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Diseases of the Esophagus·2025Open Access
327. POSITIVE IMPACT OF THE DOUBLE-FLAP TECHNIQUE FOR RECONSTRUCTION AFTER THORACOSCOPIC/LAPAROSCOPIC OR ROBOT ASSISTED IVOR-LEWIS ESOPHAGECTOMY FOR EGJ CANCER
Diseases of the Esophagus·2025
DCF-resistant ESCC redevelops drug sensitivity when combined with calcium channel blockers due to ER stress response
Esophagus·2025· 1 cited
ASO Author Reflections: Can Artificial Intelligence Improve Confidence and Timing in Recurrent Laryngeal Nerve Recognition?
Annals of Surgical Oncology·2025
Su1187: ALCOHOL CONSUMPTION, SMOKING AND THEIR CESSATION FOR FIELD CARCINOGENESIS IN THE ESOPHAGUS, HEAD, AND NECK: 10-YEAR FOLLOW-UP RESULTS FROM A MULTICENTER COHORT STUDY
Gastroenterology·2025
Detection of pathologic complete response using deep neural network-based endoscopic evaluation in patients with esophageal cancer receiving neoadjuvant chemotherapy: a nationwide multicenter retrospective study from 46 Japanese esophageal centers
Esophagus·2025· 3 cited
A phase I/II trial evaluating the safety of increased-dose S- 1 with oxaliplatin and nivolumab in HER2-negative advanced gastric cancer
BMC Cancer·2025Open Access
Oesophagectomy in the East <i>versus</i> the West: comparison of two national audit databases
British journal of surgery·2025· 4 citedOpen Access
page 1 of 18Next →

Frequent Co-authors

Yuko Kitagawa(39), Hiroya Takeuchi(31), Norihito Wada(20), Rieko Nakamura(18), Satoru Matsuda(16), Tsunehiro Takahashi(14), Kazumasa Fukuda(13), Tai Omori(11), Yoshiro Saikawa(10), Shuhei Mayanagi(8), Manabu Muto(7), Tomoyuki Irino(7), Eisuke Booka(5), Tsuneo Oyama(4), Ken Kato(4), Masahiro Yoshida(4), Koichi Suda(4), Akira Yokoyama(4), Akira Yokoyama(4), Sachiko Matsuda(4)